Ocaratuzumab
Ocaratuzumab
Ocaratuzumab (pronunciation: oh-kar-uh-too-zoo-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of immunotherapy that targets specific cells to enhance the body's immune response against cancer cells.
Etymology
The name "Ocaratuzumab" is derived from the International Nonproprietary Names (INN), where "O" stands for Oncology, "car" refers to the carbohydrate moieties in the structure, "tuzu" is a stem used for humanized antibodies, and "mab" is a common suffix for monoclonal antibodies.
Mechanism of Action
Ocaratuzumab works by binding to the CD20 antigen on the surface of cancer cells, specifically B-cell lymphomas. This binding triggers an immune response that leads to the destruction of the cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
- CD20: A protein found on the surface of B cells, a type of white blood cell.
- B-cell lymphomas: A type of cancer that forms in B cells.
See Also
External links
- Medical encyclopedia article on Ocaratuzumab
- Wikipedia's article - Ocaratuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski